Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a …

CL Arteaga, SD Hurd, AR Winnier… - The Journal of …, 1993 - Am Soc Clin Investig
CL Arteaga, SD Hurd, AR Winnier, MD Johnson, BM Fendly, JT Forbes
The Journal of clinical investigation, 1993Am Soc Clin Investig
TGF-beta effects on angiogenesis, stroma formation, and immune function suggest its
possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b,
which neutralizes TGF-beta 1,-beta 2, and-beta 3, and the MDA-231 human breast cancer
cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer
(NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal
inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas …
TGF-beta effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-beta 1, -beta 2, and -beta 3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-beta 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-beta 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF-beta in the progression of mammary carcinomas by suppressing host immune surveillance.
Images
The Journal of Clinical Investigation